In late November, BioNTech raised its full-year 2025 revenue guidance, recognizing US$700 million from its collaboration with Bristol-Myers Squibb, while reporting a net loss for the quarter due to a ...

LONDON (Reuters) -Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last ...

(Reuters) -Germany's BioNTech announced on Monday a partnership with a global coalition for up to $90 million in funding to support the development of mpox vaccine candidates. BioNTech would initiate ...

BioNTech (NASDAQ:BNTX), the partner of Pfizer (NYSE:PFE) for Comirnaty COVID-19 shot, reported its Q4 2023 financials on Wednesday, in the black, despite a ~65% drop in revenue driven by sliding ...

BioNTech SE (NASDAQ:BNTX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Clear Street analysts reiterated a Buy rating on BioNTech SE (NASDAQ:BNTX), buoyed ...

BioNTech (NASDAQ:BNTX) announced Tuesday that its mRNA-based cancer therapy BNT111, in combination with Regeneron’s (NASDAQ:REGN) anti-PD-1 therapy, Libtayo (cemiplimab), succeeded in a Phase 2 trial ...

J.P. Morgan has downgraded BioNTech SE (NASDAQ:BNTX), acknowledging the company's substantial cash reserves and limited downside potential. The analysts Jessica Fye, Na Sun, and Nick Lenard expressed ...

The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac’s issued and outstanding shares, tendered prior to the ...

MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified oncology ...

Conference call and webcast scheduled for May 5, 2025, at 8:00 a.m. EDT (2:00 p.m. CEST) MAINZ, Germany, May 5, 2025 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today ...

(Reuters) - Germany's BioNTech said on Monday that it signed a deal with Chinese biotech company DualityBio to co-develop and commercialize two cancer antibody drug candidates. DualityBio will receive ...